Detail akcie Curanex Pharma Rg online

Business Summary: Curanex Pharmaceuticals Inc is a developmental stage pharmaceutical company. The Company is engaged in discovering, developing, and commercializing botanical drugs to treat patients suffering from inflammatory diseases and to develop therapies that offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections. Its lead candidate, Phyto-N, is a botanical extract from a single plant with anti-inflammatory properties that act via multiple targets and mechanisms. Its drug development pipelines encompass six various therapeutic areas: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, and gout. Phyto-N is being developed as an orally administered alternative for patients with moderate to severe ulcerative colitis, aiming to address limitations of current treatments. The Company's two botanical drugs include Veregen (sinecatechins) and Fulyzaq/Mytesi (crofelemer).
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Curanex Pharmaceuticals Inc revenues was not reported. Net loss increased from $216K to $1.2M. Higher net loss reflects General & administrative increase from $218K to $469K (expense), Interest Expense increase from $0K to $9K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.01 to -$0.04.